In various medical and surgical conditions, research has found that centers with higher patient volumes have better outcomes. This relationship has not previously been explored for status epilepticus. This study sought to examine whether centers that see higher volumes of patients with status epilepticus have lower in-hospital mortality than low-volume centers.
Cohort study, using 2010–2015 data from the nationwide Case Mix Programme database of the U.K.’s Intensive Care National Audit and Research Centre.
Greater than 90% of ICUs in United Kingdom, Wales, and Northern Ireland.
Twenty-thousand nine-hundred twenty-two adult critical care admissions with a primary or secondary diagnosis of status epilepticus or prolonged seizure.
Annual hospital status epilepticus admission volume.
We used multiple logistic regression to evaluate the association between hospital annual status epilepticus admission volume and in-hospital mortality. Hospital volume was modeled as a nonlinear variable using restricted cubic splines, and generalized estimating equations with robust SEs were used to account for clustering by institution. There were 2,462 in-hospital deaths (11.8%). There was no significant association between treatment volume and in-hospital mortality for status epilepticus (p = 0.54). This conclusion was unchanged across a number of subgroup and sensitivity analyses, although we lacked data on seizure duration and medication use. Secondary analyses suggest that many high-risk patients were already transferred from low- to high-volume centers.
We find no evidence that higher volume centers are associated with lower mortality in status epilepticus overall. It is likely that national guidelines and local pathways in the United Kingdom allow efficient patient transfer from smaller centers like district general hospitals to provide satisfactory patient care in status epilepticus. Future research using more granular data should explore this association for the subgroup of patients with refractory and superrefractory status epilepticus.
1Department of Critical Care Medicine, University Hospital of Birmingham NHS trust, Birmingham, United Kingdom.
2Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada.
3Perioperative and Critical Care Research Group, University of Birmingham, Birmingham, United Kingdom.
4Department of Neurology, University Hospital of Birmingham NHS trust, Birmingham, United Kingdom.
This work was performed at Queen Elizabeth Hospital Birmingham, University Hospital of Birmingham NHS trust.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).
Dr. Whitehouse received a Queen Elizabeth Hospital Birmingham Charity Award for time spent on this study; he is also supported by Epilepsy Research UK unconditionally for this study; he disclosed that he is Chief Investigator for a National Institute for Health Research Efficacy and Mechanism Evaluation funded study into Septic Shock and Beta Blockade (STudy into the REversal of Septic Shock with Landiolol). Dr. Bion disclosed that he is a research advisor to Nestle, for which he receives an honorarium of less than £1,000 per year. Dr. Veenith received a Queen Elizabeth Hospital Birmingham Charity Award for time spent on this study, and he received support for article research from Queen Elizabeth hospital medical charities.
For information regarding this article, E-mail: email@example.com